» Boosted Reyataz And Lopinavir/R Achieve Similar Results For Undetectable Viral Load In Treatment-Naive HIV-1 Infected Patients
Bristol-Myers Squibb Company (NYSE: BMY) announced results from a pre-specified subanalysis of the CASTLE study, in which once-daily boosted REYATAZ® (atazanavir sulfate) (REYATAZ 300 mg taken with…